Lọc theo
Higher maternal 25-hydroxyvitamin D (25[OH]D) levels throughout pregnancy appear to reduce the likelihood of dental caries in offspring in early childhood, according to a prospective study from China.
Treatment with carbegoline is efficacious and well tolerated for reducing lactation symptoms following early second-trimester abortion or pregnancy loss, according to a study.
A trend toward increased continuous use of tumour necrosis factor inhibitors has been observed throughout gestation, which suggests growing confidence in the safety and effectiveness of this medication during pregnancy, reveals a study.
Researchers from the School of Life Sciences and the Gerald Choa Neuroscience Institute at the Chinese University of Hong Kong (CUHK) have found that estradiol (E2) to progesterone (P4) (E2:P4) imbalance during perimenopause likely increases the risk of Alzheimer’s disease (AD) and AD-related dementia in women via oestrogen-related receptor alpha (ERRα) dysfunction.
Treatment with the first-in-class oral nonazole, triterpenoid antifungal ibrexafungerp appears to be efficacious and well-tolerated in patients with recurrent vulvovaginal candidiasis, as shown in the phase III CANDLE study.
Exposure to oral corticosteroids during pregnancy is not associated with the risk of gestational diabetes mellitus (GDM), except for a modest increase during an early exposure window, as shown in a study from South Korea.
Infants exposed to antiretroviral treatment (ART) regimens containing integrase strand transfer inhibitors (INSTIs) in utero seem to fare as well as their nonexposed peers in terms of neurodevelopment, as reported in a study.
The use of aspirin among pregnant patients with inflammatory bowel disease (IBD) does not appear to increase the risk of disease severity, reports a study. Low-dose aspirin (LDA) has been prescribed to nearly a third of IBD patients during pregnancy.
Postmenopausal women with sleep-related disorders face increased risk of hypertension, according to a US-based study.
New drug applications approved by US FDA as of 16-31 October 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
